
Opinion|Videos|June 2, 2025
Patient Education, Shared Decision-Making, and Optimizing Care for ESR1-Mutated Breast Cancer
Author(s)Virginia Kaklamani, MD, DSc, Megan Kruse, MD
Panelists discuss how a multidisciplinary team approach to patient education and medication management is crucial for ensuring adherence and optimal outcomes with oral medications like elacestrant.
Advertisement
Episodes in this series

Video content above is prompted by the following:
Clinical Brief: Implementation and Patient Support Strategies
Main Discussion Topics:
- Role of multidisciplinary care team in patient education and support
- Importance of early intervention for side effect management
- Strategies for ensuring medication adherence with oral therapy
- Value of nurse coordinators and pharmacist integration
- Flexible approaches, including chemotherapy-endocrine therapy sequencing
Key Points for Physicians:
- Team-based approach crucial for successful oral therapy management
- Early touchpoints in first month prevent long-term discontinuation
- Patient education impacts adherence and anxiety management
- Consider short-course chemotherapy followed by endocrine therapy in select cases
- Communication protocols essential for optimal outcomes
The discussion highlighted that successful implementation of oral targeted therapies requires comprehensive support systems and proactive communication strategies to ensure optimal patient outcomes and treatment adherence.
Advertisement
Related to this article

During a virtual event, Neil M. Iyengar, MD, and participants discussed how approvals for trastuzumab deruxtecan before and after surgery complicate sequencing for patients with HER2-positive early breast cancer.

ER status and HER2DX score predict complete response to neoadjuvant THP in HER2-positive breast cancer, guiding smarter, less intensive chemo selection.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
VS-7375 Shows Antitumor Activity in PDAC, Other KRAS G12D–Mutant Tumors
2
ESMO 2026 Preview: Late-Breaking Studies to Watch Across Tumor Types
3
FDA Accepts BLA for Pembrolizumab Biosimilar Candidate FYB206
4
Durability of PFS and OS Benefit vs. Historical Control
5

